| SURMOUNT-MMOA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | Tirzepatide Obesity / overweight | BMI ≥27 · Established CVD | Ph 3 | Active, not recruiting | 671 | Oct 2027 | 1 | |
| SURPASS-CVOTA Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | Dulaglutide, Tirzepatide Cardiovascular disease, Type 2 diabetes | BMI ≥25 · Established CVD | Ph 3 | Completed | 635 | Jun 2025 | 4 | |
| NCT07165028A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Retatrutide, Tirzepatide MASH / NAFLD / liver fibrosis, Obesity / overweight | - | Ph 3 | Recruiting | 562 | Aug 2030 | - | |
| SURPASS-4A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk | Tirzepatide Cardiovascular disease, Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 216 | Jan 2021 | 6 | results |
| NCT06221969A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | CagriSema / cagrilintide, Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Completed | 196 | Mar 2026 | - | |
| COMMIT-UCMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study | Tirzepatide Gastrointestinal (gastroparesis / short bowel / pancreatitis), Obesity / overweight | - | Ph 3 | Recruiting | 190 | Apr 2028 | - | |
| COMMIT-CDMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight | Tirzepatide Gastrointestinal (gastroparesis / short bowel / pancreatitis), Obesity / overweight | BMI ≥30 | Ph 3 | Recruiting | 187 | May 2028 | - | |
| REIMAGINE 5A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both | CagriSema / cagrilintide, Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Active, not recruiting | 163 | Jun 2026 | - | |
| SURPASS-T1D-1A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Tirzepatide Obesity / overweight, Type 1 diabetes | BMI ≥25 | Ph 3 | Active, not recruiting | 146 | Nov 2026 | - | |
| NCT04847557A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial | Tirzepatide Heart failure, Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 146 | Jul 2024 | 7 | results |
| SURPASS-6A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin | Tirzepatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 135 | Oct 2022 | 2 | results |
| SURPASS-2A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 127 | Jan 2021 | 9 | results |
| SURPASS-3A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes | Tirzepatide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 122 | Dec 2020 | 9 | results |
| SURMOUNT-1A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight | Tirzepatide Obesity / overweight, Prediabetes / glucose intolerance | BMI ≥30 | Ph 3 | Completed | 118 | Apr 2022 | 14 | results |
| SYNERGY-NASHA Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) | Tirzepatide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 112 | Dec 2023 | 1 | results |
| NCT06326047A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes | NNC0519-0130, Tirzepatide Type 2 diabetes | HbA1c 7.5-10% | Ph 2 | Completed | 94 | Sep 2025 | - | |
| SURPASS-EARLYA Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes | Tirzepatide Type 2 diabetes | HbA1c 7-9.5% | Ph 4 | Active, not recruiting | 90 | Oct 2025 | 1 | |
| TOGETHER-PsAIxekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight | Tirzepatide Obesity / overweight, Psoriasis / psoriatic arthritis | BMI ≥30 | Ph 3 | Completed | 86 | Nov 2025 | 1 | |
| SURPASS-T1D-2A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Tirzepatide Obesity / overweight, Type 1 diabetes | BMI ≥25 | Ph 3 | Active, not recruiting | 79 | Nov 2026 | - | |
| SURMOUNT-2A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Completed | 75 | Mar 2023 | 4 | results |
| NCT06439277A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) | Tirzepatide Dyslipidemia, Hypertension, Obesity / overweight, Prediabetes / glucose intolerance | Age 12-17 | Ph 3 | Recruiting | 73 | Oct 2027 | - | |
| TOGETHER-PsOIxekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight | Tirzepatide Obesity / overweight, Psoriasis / psoriatic arthritis | BMI ≥30 | Ph 3 | Active, not recruiting | 72 | Jan 2026 | 1 | |
| SURMOUNT-4A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss | Tirzepatide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 70 | Apr 2023 | 8 | results |
| NCT06326060A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight | NNC0519-0130, Tirzepatide Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 70 | Apr 2025 | - | |
| NCT04093752A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo) | Tirzepatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 67 | Nov 2021 | 2 | results |
